KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $38.0 million.

  • Quest Diagnostics' Change in Receivables rose 4074.07% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.0 million, marking a year-over-year increase of 2173.91%. This contributed to the annual value of $71.0 million for FY2024, which is 37333.33% up from last year.
  • Latest data reveals that Quest Diagnostics reported Change in Receivables of $38.0 million as of Q3 2025, which was up 4074.07% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Quest Diagnostics' Change in Receivables registered a high of $220.0 million during Q3 2021, and its lowest value of -$138.0 million during Q1 2021.
  • For the 5-year period, Quest Diagnostics' Change in Receivables averaged around -$4.6 million, with its median value being -$12.0 million (2022).
  • As far as peak fluctuations go, Quest Diagnostics' Change in Receivables plummeted by 17937.5% in 2021, and later soared by 150000.0% in 2025.
  • Quest Diagnostics' Change in Receivables (Quarter) stood at -$36.0 million in 2021, then crashed by 133.33% to -$84.0 million in 2022, then rose by 15.48% to -$71.0 million in 2023, then increased by 2.82% to -$69.0 million in 2024, then surged by 155.07% to $38.0 million in 2025.
  • Its Change in Receivables stands at $38.0 million for Q3 2025, versus $14.0 million for Q2 2025 and $101.0 million for Q1 2025.